Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant aromatase inhibitor strategy comparison in postmenopausal endocrine-responsive breast cancer
2006-004018-42Phase 3Active
- Sponsor
- University of Naples Federico II
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole, letrozole, exemestane and tamoxifen in breast cancer (6 arms), sponsored by University of Naples Federico II. Primary endpoints: Disease-free survival, Overall survival and 1 more. Started May 2007; status: active.
02
Drugs
anastrozoleletrozoleexemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004018-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004018-42.